| DIRECT COMPETITOR COMPARISON | |
| INO | BIIB | TGEN | VICL | Industry | | Market Cap: | 122.55M | 15.11B | 5.14M | 142.49M | 104.49M | | Employees: | 27 | 4,700 | 13 | 118 | 68 | | Qtrly Rev Growth (yoy): | 701.90% | 2.50% | 113.00% | 362.40% | 19.10% | | Revenue (ttm): | 6.83M | 4.32B | 11.33M | 12.76M | 13.84M | | Gross Margin (ttm): | 7.31% | 91.12% | 25.68% | -135.73% | 64.07% | | EBITDA (ttm): | -12.25M | 1.68B | -1.99M | -25.43M | -11.86M | | Oper Margins (ttm): | -199.12% | 28.43% | -24.59% | -220.69% | -149.46% | | Net Income (ttm): | -20.64M | 869.75M | -4.65M | -30.27M | N/A | | EPS (ttm): | -0.344 | 2.988 | -0.228 | -0.686 | -0.33 | | P/E (ttm): | N/A | 17.48 | N/A | N/A | 17.48 | | PEG (5 yr expected): | N/A | 1.49 | N/A | N/A | 1.35 | | P/S (ttm): | 18.38 | 3.49 | 0.42 | 11.54 | 10.13 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.42 | 0.12% | 58.12B | 12.52 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 52.24 | 0.15% | 15.11B | 17.48 | | Genzyme Corp. | GENZ | 48.50 | 0.62% | 12.87B | 27.65 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 43.00 | -0.02% | 38.70B | 16.63 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 52.17 | 0.68% | 9.30B | 1064.69 | | Teva Pharmaceutical Industries Limited | TEVA | 55.94 | -0.07% | 49.28B | 51.18 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 39.91 | 0.28% | 4.24B | 20.57 | | King Pharmaceuticals Inc. | KG | 12.14 | -0.82% | 3.01B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.74 | 0.00% | 5.73B | 114.97 | | Pfizer Inc. | PFE | 18.60 | 0.11% | 150.09B | 15.45 | | Johnson & Johnson | JNJ | 64.70 | 0.20% | 178.51B | 14.13 | | GlaxoSmithKline plc | GSK | 42.29 | 0.48% | 107.21B | 13.87 | | Sanofi-Aventis | SNY | 39.87 | 0.43% | 104.11B | N/A | | Novartis AG | NVS | 54.84 | 0.44% | 124.55B | 16.42 |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | RHHBY.PK | 43.20 | 0.93% | N/A | N/A | | AstraZeneca plc | AZN | 46.38 | 0.89% | 67.25B | 9.31 | | Abbott Laboratories | ABT | 54.15 | 0.11% | 83.76B | 14.67 | | Bristol-Myers Squibb Co. | BMY | 25.76 | 0.23% | 51.03B | 13.33 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | BIIB | | Large-Cap Biotechs Face Familiar Problem
Thu, Dec 24 -
Investor's Business Daily | | • | BIIB | | Top 10 Stocks for Obamacare
Thu, Dec 24 -
at CNBC | | • | VICL | | [video] Biotech Stocks Under $5
Wed, Dec 23 -
at TheStreet.com | | • | BIIB | | Which Is the Best Bet: Biogen, Cepheid, or Myriad?
Wed, Dec 23 -
at Motley Fool | | • | BIIB | | The Worst Stocks to Buy Today
Tue, Dec 22 -
at Motley Fool | | • | VICL | | Early-Morning Movers: Amkor Technology, Take-Two Interactive
Tue, Dec 22 -
at Fox Business | | • | VICL | | UPDATE - Vical says gets US patent for herpes DNA vaccine
Tue, Dec 22 -
at Reuters | | • | VICL | | Vical and the University of Washington Receive U.S. Patent for Herpes Simplex DNA Vaccine
Tue, Dec 22 -
GlobeNewswire | | • | BIIB | | CEO Mullen sells $7M in Biogen Idec stock
Mon, Dec 21 -
at bizjournals.com | | • | TGEN | | Emerging Stock Report Initiates Independent Research Coverage on Targeted Genetics Corporation
Mon, Dec 14 -
GlobeNewswire | | • | VICL | | VICAL INC Files SEC form 8-K, Other Events
Thu, Dec 10 -
EDGAR Online | | • | TGEN | | TARGETED GENETICS CORP /WA/ Financials
Sat, Nov 21 -
EDGAR Online Financials | | • | TGEN | | Targeted Genetics reports $671K net income in Q3
Mon, Nov 16 -
at bizjournals.com | | • | TGEN | | TARGETED GENETICS CORP /WA/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
Mon, Nov 16 -
EDGAR Online | | • | TGEN | | Targeted Genetics Corporation Reports Third Quarter 2009 Financial Results
Mon, Nov 16 -
Business Wire | | | All Headlines for these symbols... |
|
|
|
0.51% Nasdaq 
0.03 (2.44%) 
Competitors
